Table 2.
Five pivotal trials for adjuvant trastuzumab in breast cancer.
| Study | Control arm | Trastuzumab arm | Reduction in relative risk of recurrence | DFS hazard ratio |
|---|---|---|---|---|
| NSABP B-31 (N = 2700) | AC → T | AC → TH |
Joint analysis 52% |
0.48 |
| NCCTG N9831 (N = 3300) | AC → T | AC → TH | ||
| HERA (N = 5090) | Any | Trastuzumab 1 year | 46% | 0.54 |
| BCIRG 006 (N = 3150) | AC → D | AC → DH DCH |
40% 33% |
0.49 0.61 |
| FINHer (N = 232) | D → FEC V → FEC |
DH → FEC VH → FEC |
0.42 |
NSABP, National Surgical Adjuvant Breast and Bowel Project; NCCTG, North Central Cancer Treatment Group; HERA, Herceptin Adjuvant Trial; BCIRG, Breast Cancer International Research Group; FINHer, Finland Herceptin Study. A, doxorubicin; C, cyclophosphamide; D, docetaxel; E, epirubicin; F, fluorouracil; H, trastuzumab; T, paclitaxel; V, vinorelbine; DFS, disease-free survival.